These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 35253097)
1. SARS-CoV-2 variants, immune escape, and countermeasures. Zhang Y; Zhang H; Zhang W Front Med; 2022 Apr; 16(2):196-207. PubMed ID: 35253097 [TBL] [Abstract][Full Text] [Related]
2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
3. A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. Zhang M; Liang Y; Yu D; Du B; Cheng W; Li L; Yu Z; Luo S; Zhang Y; Wang H; Zhang X; Zhang W Int J Biol Sci; 2022; 18(2):889-900. PubMed ID: 35002532 [TBL] [Abstract][Full Text] [Related]
5. Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. Bushman M; Kahn R; Taylor BP; Lipsitch M; Hanage WP Cell; 2021 Dec; 184(26):6229-6242.e18. PubMed ID: 34910927 [TBL] [Abstract][Full Text] [Related]
6. Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review. Fan Q; Nie Z; Xie S Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556935 [TBL] [Abstract][Full Text] [Related]
8. A review of the safety and efficacy of current COVID-19 vaccines. Huang Z; Su Y; Zhang T; Xia N Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Variants of Concern. Choi JY; Smith DM Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129 [TBL] [Abstract][Full Text] [Related]
10. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623 [TBL] [Abstract][Full Text] [Related]
11. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frederiksen LSF; Zhang Y; Foged C; Thakur A Front Immunol; 2020; 11():1817. PubMed ID: 32793245 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 transmissibility compared between variants of concern and vaccination status. Wang L; Didelot X; Bi Y; Gao GF Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35062017 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300 [TBL] [Abstract][Full Text] [Related]
14. The global epidemic of SARS-CoV-2 variants and their mutational immune escape. Tian D; Sun Y; Zhou J; Ye Q J Med Virol; 2022 Mar; 94(3):847-857. PubMed ID: 34609003 [TBL] [Abstract][Full Text] [Related]
15. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. Bui NN; Lin YT; Huang SH; Lin CW Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355 [TBL] [Abstract][Full Text] [Related]
16. Strategies and safety considerations of booster vaccination in COVID-19. Meng H; Mao J; Ye Q Bosn J Basic Med Sci; 2022 Jun; 22(3):366-373. PubMed ID: 35366790 [TBL] [Abstract][Full Text] [Related]
17. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM Front Immunol; 2021; 12():747830. PubMed ID: 34858404 [TBL] [Abstract][Full Text] [Related]
18. The COVID-19 pandemic: viral variants and vaccine efficacy. Ciotti M; Ciccozzi M; Pieri M; Bernardini S Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660 [TBL] [Abstract][Full Text] [Related]
19. Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2. Parums DV Med Sci Monit; 2022 Feb; 28():e936199. PubMed ID: 35102132 [TBL] [Abstract][Full Text] [Related]
20. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]